Empliciti (elotuzumab)

drip
100 % legal and regulated
Secured logistics globally
24/7 track & trace delivery
Safe payment by bank transfer or credit card

We are registered as an independent intermediary for medicines with the Dutch Ministry of Health

Empliciti (elotuzumab)

How to order Empliciti: You can order Empliciti (elotuzumab) via TheSocialMedwork if the drug has not been approved and/or is not available in the patient's country. TheSocialMedwork - helping patients and doctors access the latest approved medicines and at the lowest price possible worldwide.

Manufacturer Bristol-Myers Squibb
Disease Blood Cancer
Indication Multiple Myeloma
Mode of Action SLAMF7-directed immunostimulatory antibody (immunotherapy)
Approval Status EMA approved (EU); FDA approved (USA); TGA approved (AUS)
Strength 300 mg, 400 mg

Who is elotuzumab for?

Elotuzumab is indicated together with two other medicines (lenalidomide and dexamethasone) for the treatment of patients with multiple myeloma who have tried at least 1 [1] to 3 [2] previous cancer treatment(s).

Recommended dose

Complete information about elotuzumab dosage and administration can be found here: [2][3][4].
The standard dosage is:
  • 10 mg/kg administered intravenously every week for the first two cycles (1 cycle = 4 weeks) and every 2 weeks thereafter until disease progression or unacceptable toxicity
  • Administer with lenalidomide and dexamethasone
Consult your treating doctor for personalised dosing.

What is elotuzumab and how does it work?

Elotuzumab is a cancer medicine used in combination with lenalidomide and dexamethasone to treat patients with multiple myeloma who have received one to three prior therapies [2][3][4].
The active substance in Empliciti, elotuzumab, is a monoclonal antibody that activates the body’s immune cells to attack the multiple myeloma cancer cells. It does this by attaching to a protein on the surface of the immune cells called SLAMF7, causing them to act against the cancer cells and thereby slowing down the disease. Elotuzumab also attaches to SLAMF7 on the cancer cells, making them more vulnerable to attack by the immune cells [1].

What is elotuzumab's approval status?

Elotuzumab was approved by:
  • FDA (USA) on November 30, 2015 [5]
  • EMA (EU) on May 11, 2016 [1]
  • TGA (AUS) on September 22, 2016 [4]
for the treatment of multiple myeloma in combination with lenalidomide and dexamethasone as second or fourth line treatment.
The approvals were based on a study (ELOQUENT-2) involving 646 multiple myeloma patients [2][3][4]. The study compared the effects of taking elotuzumab plus lenalidomide and dexamethasone (N = 321) with the effects of taking only lenalidomide and dexamethasone (N = 325) [2][3][4]. Treatment was administered in 4-week cycles until disease progression or unacceptable toxicity. The evaluation was based on two parameters: the progression free survival (PFS) and the overall response rate (ORR). The PFS is the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease where it does not get worse [6]. The ORR is the portion of patients with a tumour size reduction of a predefined amount for a minimum time period [7].
The median PFS in patients that took elotuzumab in addition to lenalidomide and dexamethasone was 4.2 months longer than in patients who took lenalidomide and dexamethasone only (18.5 months (95 % CI 16.5, 21.4) vs 14.3 months (95% CI 12.0, 16.0)). The 1-year PFS rate — the portion of patients that after 1 year of treatment had no progression of their disease yet — was 68 % of the patients on the elotuzumab addition compared with 56 % of the patients on the other two drugs only. The 2-year PFS rate and the 3-year response rate were 39 % and 23 % for patients with elotuzumab and 26% and 15 % for patients without. The median ORR was 78.5 % (95 % CI 73.6, 82.9) with elotuzumab and 65.5 % (95 % CI 60.1, 70.7) without, with a complete response of 4.4 % vs. 7.4 %. The median overall survival (OS) was 43.7 months with elotuzumab and 39.6 months without [2][3][4].
References
[1] EMA. Human Medicines: Empliciti (elotuzumab), 19/05/2016 (last update: 15/12/2016), cited on 16/03/2017.
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003967/human_med_001968.jsp&mid=WC0b01ac058001d124
[2] Summary of Product Characteristics: Empliciti (elotuzumab), Bristol-Myers Squibb, FDA, May 2017.
https://packageinserts.bms.com/pi/pi_empliciti.pdf
[3] Summary of Product Characteristics: Empliciti (elotuzumab), Bristol-Myers Squibb, EMA, Dec 2016.
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003967/WC500206673.pdf
[4] Summary of Product Characteristics: Empliciti (elotuzumab), Bristol-Myers Squibb Australia, TGA, Sep 2016.
https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2016-PI-02539-1
[5] Drugs.com. Empliciti (elotuzumab), (last update: 14/01/2016), cited on 16/03/2017.
https://www.drugs.com/empliciti.html
[6] NIH National Cancer Institute. NCI Dictionary of Cancer Terms: progression-free survival, cited on 16/03/2017.
https://www.cancer.gov/publications/dictionaries/cancer-terms?cdrid=44782
[7] Pazdur R., Endpoints for Assessing Drug Activity in Clinical Trials. The Oncologist. 2008 Apr; 13(2):19-21.
http://theoncologist.alphamedpress.org/content/13/suppl_2/19.full.pdf+html

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Medicine information contained herein may be time sensitive. The absence of a warning for a given medicine or combination thereof in no way should be construed to indicate that the medicine or combination is safe, effective or appropriate for any given patient. Always consult your treating physician before starting a course of treatment.

How can we help?

★ ★ ★ ★ ★
 
 

We've received requests for support from patients and doctors in over 120 countries, and delivered medicines to 6 continents. They've given us a 5 star rating for our service. Read what our friends from around the world are saying...

"My experience has been excellent. TheSocialMedwork were totally knowledgeable about the medicine I was looking for, and how to get it delivered to me quickly and easily. I UNCONDITIONALLY recommend TSM to anyone, it is truly a world-class organisation."

— Charles, USA

"During the transaction process I was very well informed by TheSocialMedwork team. They have put so much effort to ensure the best service was offered to me. Moreover the medicine I ordered was imported two weeks earlier. I highly recommend TheSocialMedwork."

— Tomasz, Poland

"I hope you know how needed you are and what it means to get a prompt, succinct and helpful reply. You are our hero. You have given us realistic hope in obtaining needed drugs in a timely way."

— Regina, US

"TheSocialMedwork were so helpful in getting the right medication to me, expediting its delivery, and keeping in touch. They simply can't do enough to help you. I would not hesitate to recommend TheSocialMedwork to anybody. Lovely people."

— Stephen, UK

"Totally awesome! Keep up the great work you're doing!"

— Dee, Australia

"When the doctor tells you that there are no treatments left to try, search further - there may be new treatments in other countries."

— Charlotte, The Netherlands

"TheSocialMedwork's professional capabilities, kindness and patience deserve our gratitude and respect."

— Haoyu, China

"My daughter died at the age of 21 because she couldn't get the treatment that might have saved her life. Now TheSocialMedwork might be able to help people like Abigail to get the best treatment."

— Frank, Virginia, USA

"The team is highly professional, friendly and will take care of everything. More options for doctor and patients. This service is transparent, unique and necessary. Keep it up!"

— Pa Tric, Germany

"Excellent communication and clarifications given every time when requested. They also provide fantastic support and updates from the start till the end of the process of the medicine provisioning."

— Milos, Serbia & Montenegro

Registered with the Dutch Ministry of Health as an independent intermediary, Registration number 6730 BEM
Registered as a USA Delaware LLC.



Our service uses cookies.